{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:11:14Z","timestamp":1794370274344,"version":"4.9.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03675-9","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:25:58Z","timestamp":1763137558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease"],"prefix":"10.1186","volume":"27","author":[{"given":"Shuai","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenguo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"3675_CR1","doi-asserted-by":"publisher","first-page":"2024869","DOI":"10.1155\/2020\/2024869","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li Y, Li Y, Wu J, Miao M, Gao X, Cai W, et al. Predictors of poor outcome of Anti-MDA5-Associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis. J Immunol Res. 2020;2020:2024869.","journal-title":"J Immunol Res"},{"issue":"2","key":"3675_CR2","doi-asserted-by":"publisher","first-page":"e1007582","DOI":"10.1371\/journal.ppat.1007582","volume":"15","author":"JP Lin","year":"2019","unstructured":"Lin JP, Fan YK, Liu HM. The 14-3-3\u03b7 chaperone protein promotes antiviral innate immunity via facilitating MDA5 oligomerization and intracellular redistribution. PLoS Pathog. 2019;15(2):e1007582.","journal-title":"PLoS Pathog"},{"issue":"4","key":"3675_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/joim.13607","volume":"293","author":"Q Jin","year":"2023","unstructured":"Jin Q, Fu L, Yang H, Chen X, Lin S, Huang Z, et al. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis. J Intern Med. 2023;293(4):494\u2013507.","journal-title":"J Intern Med"},{"issue":"1","key":"3675_CR4","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology. 2020;95(1):e70\u20138.","journal-title":"Neurology"},{"key":"3675_CR5","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with Anti-MDA5 antibodies: bioclinical Features, pathogenesis and emerging therapies. Front Immunol. 2021;12:773352.","journal-title":"Front Immunol"},{"issue":"2","key":"3675_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-020-08822-5","volume":"60","author":"W Wu","year":"2021","unstructured":"Wu W, Guo L, Fu Y, Wang K, Zhang D, Xu W, et al. Interstitial lung disease in Anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol. 2021;60(2):293\u2013304.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"3675_CR7","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018;57(12):2114\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"3675_CR8","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1093\/brain\/awz293","volume":"142","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using Tofacitinib. Brain. 2019;142(11):e59.","journal-title":"Brain"},{"issue":"3","key":"3675_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in amyopathic Dermatomyositis-Associated interstitial lung disease. N Engl J Med. 2019;381(3):291\u20133.","journal-title":"N Engl J Med"},{"issue":"4","key":"3675_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40674-021-00186-x","volume":"7","author":"A Selva-O\u2019Callaghan","year":"2021","unstructured":"Selva-O\u2019Callaghan A, Romero-Bueno F, Trallero-Aragu\u00e1s E, Gil-Vila A, Ruiz-Rodr\u00edguez JC, S\u00e1nchez-Pernaute O, et al. Pharmacologic treatment of Anti-MDA5 rapidly progressive interstitial lung disease. Curr Treatm Opt Rheumatol. 2021;7(4):319\u201333.","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"3","key":"3675_CR11","doi-asserted-by":"publisher","first-page":"e14939","DOI":"10.1111\/dth.14939","volume":"34","author":"A Paudyal","year":"2021","unstructured":"Paudyal A, Zheng M, Lyu L, Thapa C, Gong S, Yang Y, et al. JAK-inhibitors for dermatomyositis: A concise literature review. Dermatol Ther. 2021;34(3):e14939.","journal-title":"Dermatol Ther"},{"key":"3675_CR12","doi-asserted-by":"crossref","unstructured":"Ida T, Furuta S, Takayama A, Tamura J, Hayashi Y, Abe K et al. Efficacy and safety of dose escalation of Tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open. 2023;9(1).","DOI":"10.1136\/rmdopen-2022-002795"},{"issue":"6","key":"3675_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/RHU.0000000000002010","volume":"29","author":"S Li","year":"2023","unstructured":"Li S, Li S, Wang J, Zhang L, Duan J, Lu X, et al. Efficacy and safety of Tofacitinib in Anti-Melanoma Differentiation-Associated 5 gene Antibody-Positive dermatomyositis. J Clin Rheumatol. 2023;29(6):281\u20134.","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"3675_CR14","first-page":"348","volume":"41","author":"JJ Paik","year":"2023","unstructured":"Paik JJ, Lubin G, Gromatzky A, Mudd PN Jr., Ponda MP, Christopher-Stine L. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. 2023;41(2):348\u201358.","journal-title":"Clin Exp Rheumatol"},{"key":"3675_CR15","doi-asserted-by":"publisher","first-page":"1158768","DOI":"10.3389\/fmed.2023.1158768","volume":"10","author":"G La Rocca","year":"2023","unstructured":"La Rocca G, Ferro F, Baldini C, Libra A, Sambataro D, Colaci M, et al. Targeting intracellular pathways in idiopathic inflammatory myopathies: A narrative review. Front Med (Lausanne). 2023;10:1158768.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"3675_CR16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","volume":"50","author":"F Romero-Bueno","year":"2020","unstructured":"Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu\u00e1s E, Ruiz-Rodr\u00edguez JC, Castellvi I, Rodriguez-Nieto MJ, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020;50(4):776\u201390.","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"3675_CR17","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1093\/rheumatology\/keaa184","volume":"59","author":"P Delvino","year":"2020","unstructured":"Delvino P, Bartoletti A, Monti S, Biglia A, Montecucco C, Carducci M, et al. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis. Rheumatology (Oxford). 2020;59(12):e125\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"3675_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00296-024-05551-2","volume":"44","author":"H Harada","year":"2024","unstructured":"Harada H, Shoda H, Tsuchiya H, Misaki M, Sawada T, Fujio K. Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease. Rheumatol Int. 2024;44(5):961\u201371.","journal-title":"Rheumatol Int"},{"issue":"12","key":"3675_CR19","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European league against Rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271\u201382.","journal-title":"Arthritis Rheumatol"},{"key":"3675_CR20","doi-asserted-by":"crossref","unstructured":"Mammen AL, Allenbach Y, Stenzel W, Benveniste O. 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018. Neuromuscul Disord. 2020;30(1):70\u201392.","DOI":"10.1016\/j.nmd.2019.10.005"},{"issue":"Suppl 1","key":"3675_CR21","first-page":"9","volume":"9","author":"H Kawasumi","year":"2015","unstructured":"Kawasumi H, Gono T, Kawaguchi Y, Yamanaka H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):9\u201317.","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"issue":"1","key":"3675_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1148\/radiol.2373041515","volume":"238","author":"K Ichikado","year":"2006","unstructured":"Ichikado K, Suga M, Muranaka H, Gushima Y, Miyakawa H, Tsubamoto M, et al. Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: validation in 44 cases. Radiology. 2006;238(1):321\u20139.","journal-title":"Radiology"},{"issue":"5","key":"3675_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/acr.22728","volume":"68","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-Melanoma Differentiation-Associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken). 2016;68(5):689\u201394.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"3675_CR24","first-page":"189","volume":"16","author":"S Pakhale","year":"2009","unstructured":"Pakhale S, Bshouty Z, Marras TK. Comparison of per cent predicted and percentile values for pulmonary function test interpretation. Can Respir J. 2009;16(6):189\u201393.","journal-title":"Can Respir J"},{"issue":"3","key":"3675_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.resinv.2019.12.003","volume":"58","author":"N Aiko","year":"2020","unstructured":"Aiko N, Yamakawa H, Iwasawa T, Takemura T, Okudela K, Kitamura H, et al. Clinical, radiological, and pathological features of anti-asparaginyl tRNA synthetase antibody-related interstitial lung disease. Respir Investig. 2020;58(3):196\u2013203.","journal-title":"Respir Investig"},{"issue":"9","key":"3675_CR26","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3675_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","volume":"20","author":"X Lu","year":"2024","unstructured":"Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol. 2024;20(1):48\u201362.","journal-title":"Nat Rev Rheumatol"},{"key":"3675_CR28","doi-asserted-by":"publisher","first-page":"978708","DOI":"10.3389\/fimmu.2022.978708","volume":"13","author":"X Gui","year":"2022","unstructured":"Gui X, Li W, Yu Y, Zhao T, Jin Z, Meng K, et al. Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease. Front Immunol. 2022;13:978708.","journal-title":"Front Immunol"},{"issue":"3","key":"3675_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with High-Dose Glucocorticoid, Tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by Anti-Melanoma Differentiation-Associated gene 5-Positive dermatomyositis. Arthritis Rheumatol. 2020;72(3):488\u201398.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"3675_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","volume":"59","author":"H You","year":"2020","unstructured":"You H, Xu D, Zhao J, Li J, Wang Q, Tian X, et al. JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol. 2020;59(3):334\u201351.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"3675_CR31","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective Inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298\u2013307.","journal-title":"J Immunol"},{"issue":"9","key":"3675_CR32","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1002\/art.34500","volume":"64","author":"C Dees","year":"2012","unstructured":"Dees C, Tomcik M, Palumbo-Zerr K, Distler A, Beyer C, Lang V, et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis. Arthritis Rheum. 2012;64(9):3006\u201315.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3675_CR33","doi-asserted-by":"publisher","first-page":"e22336","DOI":"10.1096\/fj.202101436R","volume":"36","author":"S Wang","year":"2022","unstructured":"Wang S, Liu M, Li X, Zhang J, Wang F, Zhang C, et al. Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. Faseb J. 2022;36(6):e22336.","journal-title":"Faseb J"},{"issue":"1","key":"3675_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42358-023-00305-3","volume":"63","author":"D Wang","year":"2023","unstructured":"Wang D, Wei Y, Xu L, Zhang J. Crosstalk between the JAK2 and TGF-\u03b21 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib. Adv Rheumatol. 2023;63(1):22.","journal-title":"Adv Rheumatol"},{"issue":"1","key":"3675_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12931-018-0728-9","volume":"19","author":"J Milara","year":"2018","unstructured":"Milara J, Hernandez G, Ballester B, Morell A, Roger I, Montero P, et al. The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):24.","journal-title":"Respir Res"},{"issue":"9","key":"3675_CR36","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51(9):1563\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3675_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14397595.2017.1318468","volume":"28","author":"Y Fujiki","year":"2018","unstructured":"Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, et al. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol. 2018;28(1):133\u201340.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"3675_CR38","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1093\/rheumatology\/keaa266","volume":"59","author":"W Huang","year":"2020","unstructured":"Huang W, Ren F, Luo L, Zhou J, Huang D, Pan Z, et al. The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease. Rheumatology (Oxford). 2020;59(12):3886\u201391.","journal-title":"Rheumatology (Oxford)"},{"key":"3675_CR39","doi-asserted-by":"crossref","unstructured":"Wu W, Guo B, Sun W, Chen D, Xu W, Chen Z et al. Effectiveness and safety of Tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multi-centre cohort study. Eur Respir J. 2025.","DOI":"10.1183\/13993003.01488-2024"},{"key":"3675_CR40","doi-asserted-by":"publisher","first-page":"740154","DOI":"10.3389\/fmed.2021.740154","volume":"8","author":"L Huang","year":"2021","unstructured":"Huang L, Zhu W, Ye Y, Wu X, Yan Q, Wang Z, et al. Association of cytomegalovirus infection with Anti-MDA5 Antibody-Positive dermatomyositis: A prospective cohort study. Front Med (Lausanne). 2021;8:740154.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"3675_CR41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.55563\/clinexprheumatol\/yps7ai","volume":"40","author":"YP Ge","year":"2022","unstructured":"Ge YP, Shu XM, He LR, Wang GC, Lu X. Infection is not rare in patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2022;40(2):254\u20139.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03675-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03675-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03675-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T19:03:49Z","timestamp":1763406229000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03675-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3675"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03675-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol was granted approval by the Ethics Committee of the China Japan Friendship Hospital (reference number 2022-KY-156). All patients signed an informed consent form on admission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}